Trial Profile

A Phase I, Single-center, Randomized, Double-blind, Placebo-controlled Design to Evaluate the Pharmacokinetics and Effects on QT Interval of a Single Oral Dose of FCN-437c Capsule in Healthy Subjects.

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 12 Mar 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs FCN 437 (Primary)
Indications Advanced breast cancer; Breast cancer; Male breast cancer; Solid tumours
Focus Pharmacokinetics
Sponsors Ahon Pharmaceutical; Chongqing Fochon Pharmaceutical

26 Feb 2024 Status changed from recruiting to completed.
26 Jun 2019 According to a Fochon Pharmaceuticals media release, the company had received the approval from China NMPA (formerly the China Food and Drug Administration or CFDA) for the IND application of FCN-437 to treat patients with solid tumors.
26 Jun 2019 Status changed from planning to recruiting, according to a Fochon Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com